To support the chemistry, manufacturing and control (CMC) and preclinical development of an inactivated rotavirus vaccine.

To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.

To show the health impact of low-cost, Indian-made rotavirus vaccines in high burden, low-income countries of Africa and Asia.

To provide evidence about the public health impact and benefits on child health after the introduction of rotavirus vaccine into the Pakistan National Immunization Program system.

To strengthen vaccine-preventable disease surveillance platforms to maximize their capacity to measure burden of disease and to monitor the impact of vaccines. Activities include improving immunization data quality; evaluating impact and implementation of vaccines (including oral cholera, rubella, and HPV); improving the quality and planning of measles and rubella campaigns; and strengthening surveillance for vaccine preventable diseases (meningitis, diphtheria and pertussis, intussusception).

To generate data on the effectiveness and impact of rotavirus vaccination in early introducing regions of India and help establish a platform for assessment of safety with respect to intussusception.

To determine the performance characteristics of tacrolimus-based (TAC) genotyping in comparison to conventional genotyping assays to better assess the role of different enteric pathogens in diarrhea requiring hospitalization among children less than five years of age. The technology will advance the analysis of rotavirus vaccine effectiveness studies by revealing how often cases of rotavirus vaccine failure are actually infections due to other enteric pathogens.